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Abstract
Background: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-
positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the
immune infiltrate in these molecular subtypes and its impact on clinical outcome, an in-depth study of the tumor
immune microenvironment was performed.
Methods: Sixty-five patients with invasive VSCC matched for age, FIGO stage and treatment modality, were
grouped according to the presence of HPV and p53 protein expression status. Archived tissues were analyzed for
intraepithelial and stromal expression of CD3, CD8, Foxp3, PD-1, and pan-keratin in randomly selected areas using
immunofluorescence. Additional phenotyping of T cells was performed ex-vivo on VSCC (n = 14) and blood
samples by flow cytometry. Healthy vulvar samples and blood served as controls.
Results: Based on T-cell infiltration patterns about half of the VSCC were classified as inflamed or altered-excluded
while one-third was immune-deserted. High intraepithelial helper T cell infiltration was observed in 78% of the HPV-
induced VSCC, 60% of the HPVnegVSCC/p53wildtype and 40% of the HPVnegVSCC with abnormal p53 expression.
A high intraepithelial infiltration with activated (CD3+PD-1+), specifically helper T cells (CD3+CD8−Foxp3−), was
associated with a longer recurrence-free period and overall survival, irrespective of HPV and p53 status. Flow
cytometry confirmed the tumor-specific presence of activated (CD4+PD-1++CD161−CD38+HLA-DR+ and
CD8+CD103+CD161−NKG2A+/−PD1++CD38++HLA-DR+) effector memory T cells.
Conclusion: This is the first study demonstrating an association between intraepithelial T cells and clinical outcome
in VSCC. Our data suggest that abnormal p53 expressing VSCCs mostly are cold tumors whereas HPV-driven VSCCs
are strongly T-cell infiltrated.
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Introduction
Immunotherapy of cancer has established itself as a new
breakthrough approach that offers long-term durable
clinical responses in patients with advanced cancers. As
the initiation and regulation of the immune response to
tumors is complex and multistep in nature, inspection of
the different processes involved is required to provide
the optimal (combination) of immunotherapeutic
modalities available [1]. This is highly relevant for vulvar
squamous cell carcinoma (VSCC), the predominant
histologic subtype of vulvar cancers, for which new
treatment options are urgently needed. Because despite
current treatment, consisting of radical surgery and/or
(chemo) radiotherapy which causes impressive morbid-
ity, lymphedema, sexual and psychological dysfunction
and wound healing disorders [2, 3], 46% of VSCC
patients still develop recurrences after 10-years [4].
At this point however, little is known about the role and
impact of cellular immunity on the clinical outcome of
VSCC. Both CD4 and CD8 T cells as well as B cells infil-
trate VSCC [5–7]. The CD4 cells comprise CD4+ helper T
cells and regulatory T cells (Tregs). Often a strong infiltra-
tion with one type of T cells is paralleled by the others [5,
6, 8]. In three studies focussing on the prognostic role of
CD4+ and/or CD8+ T cells or Tregs no impact on clinical
outcome was found [6, 9, 10]. On the one hand, these ana-
lyses may have been influenced by the heterogeneity of the
study group with respect to tumor etiology, stage and treat-
ment. Furthermore, enumeration of all T cells, irrespective
of their location in the tumor [9], as well as preselection of
highly infiltrated areas only [6, 10], may also have influ-
enced study outcomes. On the other hand, the impact of T
cells may be nullified by the presence of immune regulatory
mechanisms, as VSCC can be massively infiltrated with M2
macrophages and Tregs [8]. Moreover, VSCC can express
the immunoregulatory enzyme, indoleamine 2,3-dioxygen-
ase (IDO) or PD-L1, both of which were shown to nega-
tively influence clinical outcome [10, 11]. Notably, PD-L1
was mainly expressed in lymphocyte rich areas [11], sug-
gesting that it functioned as an adaptive escape mechanism
[12], and implying that in some VSCC a functionally active
antitumor response is present. This notion is sustained by
the observation that the intraepithelial presence of Gran-
zyme B-positive cells is related to better overall survival
(OS) in patients with localized VSCC [13].
At present, three distinct etiologic pathways in the
development of VSCC have been proposed. One type is
driven by the overexpression of high-risk human papilloma
virus oncogenes E6 and E7 (HPVposVSCC). The second
type is not related to HPV and can be categorized based on
the mutational status of the tumor suppressor gene TP53
associated with high protein levels of p53 (HPVnegVSCC/
p53abn). We recently identified a third type as a substantial
group of patients with a HPV-negative VSCC displaying
normal expression levels of p53 protein (HPVnegVSCC/
p53wt) but frequently bearing other mutations [14].
Importantly, HPV-driven VSCC display better OS and a
longer recurrence-free period (RFP) than HPVnegVSCC
[14–17]. Interestingly among the latter group, local recur-
rences more often occurred after treatment in patients with
HPVnegVSCC/p53abn than in HPVnegVSCC/p53wt [14].
With the first reports showing an influence of different
oncogenic pathways on local immunity [18, 19], we asked
the question if the differences in RFP and OS observed
between the three groups of VSCC driven by different
oncogenic pathways could be explained by the local im-
mune response. Bearing in mind the limitations of previous
studies, we selected three cohorts of VSCCs based on their
HPV and p53 protein (abn/wt) status which were highly
matched for clinicopathological parameters and enumer-
ated different types of intraepithelial and stromal T cells in
randomly selected fields of VSCC, using multiplex im-
munofluorescence. In-depth analysis of T cells was per-
formed on freshly dispersed tissue by flow cytometry. Our
study revealed a strong impact of intraepithelial activated T
cells on clinical outcome, in particular a dense infiltration
with intraepithelial CD4+ T cells was highly associated with
RFP and OS, irrespective of HPV or p53 status. Moreover,
the percentage of tumors highly infiltrated with these T
cells varied between the three different subtypes, with
HPV-induced VSCC most often strongly infiltrated (78%)
followed by the HPVnegVSCC/p53wt (60%) and the lowest
infiltration in the HPVnegVSCC/p53abn group (40%).
Material and methods
Patient materials
Archived formalin-fixed paraffin-embedded (FFPE) tumor
tissue from VSCC patients was selected from a larger co-
hort with known HPV and p53 status. HPV presence was
tested by HPV-PCR and p16 IHC [20]. Tumors that were
positive in both tests were assigned as HPVposVSCC.
When both tests were negative, tumors were scored as
HPVnegVSCC. The HPVnegVSCC were further sub-classi-
fied based on the wildtype or abnormal expression of p53
(HPVnegVSCC/p53wt and HPVnegVSCC/p53abn) as pre-
viously described [14]. In addition, archived FFPE healthy
HPV-negative vulvar tissue from 10 women who under-
went labial reduction surgery served as controls. Fresh
tumor tissue (n = 14) and blood samples (n = 34) were ob-
tained from 38 patients participating in the large observa-
tional CIRCLE study. Women with histologically proven
p16ink4a-negative VSCC were included in this study investi-
gating cellular immunity against anogenital lesions [21, 22].
Tumor staging was done according to FIGO staging 2009.
Patients were included after signing informed consent. The
study was conducted in accordance with the Declaration of
Helsinki and approved by the local medical ethical commit-
tee of the Leiden University Medical Center (P08.197 and
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B16.024) and in agreement with the Dutch law. The mate-
rials were used according to the Dutch Federation of
Medical Research Association guidelines. The patients
received standard-of-care treatment consisting of pri-
mary surgery.
Multiplex six color staining, image acquisition and
analysis by VECTRA
For the direct and indirect immunofluorescent six
color staining and detection, 4 μm FFPE tissue sec-
tions were deparaffinized and prepared with heat-in-
duced antigen citrate (10 mM, pH 6.0) retrieval as
described previously [23]. Antibody specificity and
optimal conditions for antigen retrieval were assessed
by single-plex IHC using tonsils as a positive control
[23]. After incubation with superblock buffer (Thermo
Fisher Scientific, Waltham, MA, USA), the primary
antibodies and isotype/species-specific secondary
fluorescent antibodies were applied (Additional file 1).
Nuclear counterstain was obtained with DAPI. Tissue
slides were imaged at 20x magnification with the
Vectra 3.0 Automated Quantitative Pathology Imaging
System (Perkin Elmer). Imaging analysis and spectral
separation of dyes was performed with the InForm
Cell Analysis software (Perkin Elmer) by using spectral
libraries defined with single-marker immunofluores-
cence detection. Five random multispectral imaging
fields of interest were selected for acquisition from
each tumor, depending on its size. Tissue and cellular
segmentation was done as described before [23]. The follow-
ing phenotypes were identified for the T cell panel: total T
cells (CD3+), CD8+ T cells (CD3+CD8+Foxp3−), helper T
cells (CD3+CD8−Foxp3−), Tregs (CD3+CD8−Foxp3+), PD-1
expressing T cells (CD3+PD1+). All images were visually
inspected to confirm the correct attribution and quantifica-
tion of phenotypes, and segmentation of tissue. Because PD-
1 could be expressed by CD3+CD8− and CD3+CD8+ cells,
the CD3+PD1+ phenotypes were separately analyzed. All
phenotypes in both areas were normalized by tissue area
(number of cells/mm2). In addition, ten HPVposVSCC,
six HPVnegVSCC/p53wt and five HPVnegVSCC/p53abn
VSCC samples were used to study Tbet (Santa Cruz,
clone H-210, dilution 1:100) expressing CD3+ cells with
immunofluorescence.
Blood and tumor cell isolation and culturing
Venous blood samples were drawn prior to surgery,
and peripheral blood mononuclear cells (PBMC) were
isolated using Ficoll density gradient centrifugation as
described previously [24, 25]. VSCC tumor material
was obtained and handled as described [24, 25]. First,
tumor material was cut into small pieces. One-third of
the tumor pieces was incubated for 60 min at 37 °C in
Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco
by life technologies, ThermoFisher Scientific, Lonza,
Verviers, Belgium) with 10% human AB serum (Capricorn
Scientific, Esdorfergrund, Germany) and supplemented
with high dose of antibiotics (50 μg/ml Gentamycin
(Gibco/ Thermo Fisher Scientific (TFS), Bleiswijk, the
Netherlands), 25 μg/ml Fungizone (Gibco/Thermo Fisher
Scientific), after which the tumor pieces were put in cul-
ture in IMDM supplemented with 10% human AB serum
(IMDM complete) and 1000 IU/ml human recombinant
IL-2 (Aldesleukin, Novartis, Arnhem, the Netherlands).
Cultures (n = 14) were replenished every 2–3 days with
fresh IMDM complete and IL-2 to a final concentration of
1000 IU/ml. After 2–4 weeks, when sufficient T cells were
obtained, the cells were cryopreserved and stored in liquid
nitrogen until use. Approximately two-third of the tumor
pieces was incubated for 15min at 37 °C in IMDM
dissociation mixture containing 10% human AB serum,
high dose of antibiotics (as above) and 0.38mg/ml of the
commercially available Liberase enzymes (Liberase TL,
research grade, Roche). Following incubation, cell suspen-
sion was put on a 70 μm cell strainer (Falcon, Durham,
NC, USA) to obtain a single cell suspension, counted
using trypan blue exclusion (Sigma, St Louis, MO, USA),
and cryopreserved at approximately 2 million cells/vial.
All cells were stored in the vapor phase of liquid nitrogen
until further use.
Flow cytometry and data analysis
Cryopreserved PBMC (n = 34) and/or cryopreserved
freshly isolated single cell tumor samples (n = 12) were
thawed and assessed by flow cytometry as described
before [26, 27]. In brief, samples were thawed according
to standard operation procedures and stained with the
LIVE-DEAD® Fixable yellow dead cell stain kit (Thermo
Fisher Scientific) for 20 min at room temperature to
identify dead cells. Following incubation, the cells were
washed, incubated with PBS/0.5%BSA/10%FCS for 10min
on ice to block Fc receptors. After the cells were washed,
the cells were stained for 30min on ice and in the dark
with fluorochrome-conjugated antibodies. Intracytoplas-
mic/intranuclear staining was conducted with the BD
Pharmingen Transcription Factor Buffer set (BD Biosci-
ences) according to manufacturers’ protocol. Details on
antibodies used are listed in Additional file 1. Acquisition
of cells was done on a BD LSR Fortessa. Data was ana-
lyzed by either manual gating using DIVA software (ver-
sion 8.02; BD Biosciences) or by high-dimensional single
cell data analysis using hierarchical Stochastical Neighbor
Embedding (HSNE) [28] in Cytosplore. To automatically
discover stratifying biological signatures at the single cell
level, we used the fully automated hierarchical clustering
(unsupervised) tool CITRUS in the cloud-based cytobank
software (Fluidigm Sciences) with an FDR of 1%.
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Cytokine production of phytohemagglutinin (PHA)-
stimulated TIL
To determine capacity of tumor infiltrating lymphocyte
(TIL) batches from HPVnegVSCC tumors to produce
cytokines in response to mitogenic stimulation, cultured
TIL batches (n = 14) were stimulated with 0.5 μg/ml PHA
(HA16 Remel; ThermoFischer Scientific) for 4 days, after
which supernatants were harvested and analyzed by
Cytometric Bead Array (CBA, Th1/Th2 kit, BD Bioscience,
Breda, the Netherlands) according to the manufacturer’s in-
structions. The cut-off value for cytokine production was
20 pg/ml, except for IFN-γ for which it was 100 pg/ml.
Positive cytokine production was defined as at least twice
above that of the unstimulated cells [25, 29].
Statistical analysis
For data analysis the statistical software package SPSS
23.0 (SPSS Inc., Chicago, IL) was used. Group compari-
sons of categorical data were performed by chi-square test.
The non-parametric Mann-Whitney U test was used for
continuous variables when comparing two groups. For the
survival analysis, patients were categorized into two
groups based on numerical immune cell count. First, the
median cell count was used as cut-off value. To optimize
the chance to detect a relationship between T-cell subsets
and clinical outcome in a relatively small group of pa-
tients, the best cut-off value for the different T cell subsets
was determined using receiver operating characteristics
(ROC) curve analysis. The T-cell subset values with the
best accuracy (i.e. with greatest sensitivity and specificity)
were selected as the most optimal cut-off value for (OS or
RFP). Based on these cut-off values, the immune cell
counts were categorized in two groups and a log-rank test
was performed to calculate the difference in OS or RFP.
The RFP was censored for lost-to-follow up and death.
Two sided p-values < 0.05 were considered significant.
GraphPad Prism 7 (GraphPad Software Inc., LA Jolla, CA,
USA) was used to illustrate the data by graphs and figures.
Results
Patient cohort
A cohort of 65 primary VSCC samples, divided in
HPVposVSCC (n = 23), HPVnegVSCC/p53wt (n = 20), and
HPVnegVSCC/p53abn (n = 22) was analyzed. All cases were
matched for age (40–85 years), FIGO stage, absence of lymph
node and distant metastasis, ≥8mm tumor-free margins, no
use of immunosuppression, and no documented medical his-
tory. However, HPVposVSCC were younger than the other
groups despite matching because younger women are more
likely to have HPVposVSCC than HPVnegVSCC [30]. An
overview of patient characteristics and treatment is given in
Additional file 2. In line with current literature [15, 17, 31],
the group of patients with HPVposVSCC displayed a better
OS andRFP than those withHPVnegVSCC (Additional file 3).
Furthermore, the recurrence rate increased from
HPVposVSCC (13%), HPVnegVSCC/p53wt (40%) to
59% in HPVnegVSCC/p53abn (Additional file 2). To-
gether this confirms our selection of a representative
cohort of patients for our study.
The HPVposVSCCs are most often strongly infiltrated with
T cells
The archived tissues sections were simultaneously analyzed
for the expression of CD3, CD8, Foxp3, PD-1, and pan-kera-
tin by multispectral immunofluorescence VECTRA analysis,
both in the epithelial and stromal compartments (Add-
itional file 4). Quantification of the T cells per square mm of
tumor revealed that the stroma of VSCC was more densely
infiltrated with CD3+ T cells, CD3+CD8−Foxp3− T cells,
CD3+CD8−Foxp3+ Tregs, and CD3+CD8+Foxp3− T cells
than healthy controls. The number of intraepithelial Tregs
was also higher in VSCC (Fig. 1; Additional file 4; Additional
file 5). Comparison of the three subgroups revealed a
strong difference in T cell infiltration between
HPVposVSCC and HPVnegVSCC/p53abn. The major-
ity of HPVposVSCC was well infiltrated whereas the
HPVnegVSCC/p53abn most often displayed a low T-
cell infiltration. The group of HPVnegVSCC/p53wt
showed a more variable pattern, with low and high T-cell
infiltrated tumors (Fig. 1; Additional file 4; Additional file 5).
The number of tumor-infiltrating intraepithelial cells was
highly correlated to the other intraepithelial T-cell subsets
and to their numbers in the stroma (Additional file 6). This
suggests a coordinated response of CD3+CD8−Foxp3− and
CD3+CD8+Foxp3− T cells in VSCC. Quantification of intrae-
pithelial CD3+Tbet+ T cells, representing type 1 immunity
[27], revealed higher numbers in HPVposVSCC compared
to both HPVnegVSCC subtypes (Fig. 1; Additional file 5).
Immune inflamed, altered-excluded, altered-
immunosuppressed and deserted VSCC
Based on the previously published categories of T-cell
infiltration patterns [32], the VSCC were characterized
(Fig. 2) as immune-deserted (n = 19), −altered (n = 41) or
-inflamed (n = 5). The immune-altered group was the
largest and could be subdivided based on two distinct pat-
terns of T cells in the stroma [33]. The altered-excluded
tumors (n = 24) showed more stromal T cells at the inva-
sive border whereas in the altered-immunosuppressed
VSCC (n = 17) T cells were dispersed throughout the
whole stroma (Fig. 2). Notably, the number of CD3+ T
cells at the invasive border (Fig. 2c) was highly correlated
with the intraepithelial CD3+ T-cell count (p = 0.000;
Additional file 6) in the altered-excluded VSCC. More-
over, the average number of intraepithelial CD3+ T cells
in the altered-excluded was higher than in the altered-im-
mune suppressed (mean 612 ± SD 539 vs mean 157 ± SD
92, p < 0.001, respectively). To evaluate the impact of
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these four VSCC categories on survival, a Kaplan-Meier
analysis was performed. The immune-inflamed group
displayed a superior RFP and OS (Additional file 7). Inter-
estingly, the group of altered-excluded VSCC showed a
similar OS whereas the RFP was less good when com-
pared to that of the immune-inflamed group. Therefore,
the immune inflamed and altered-excluded VSCC were
classified as hot tumors.
The intratumoral CD3+CD8−Foxp3− T cell count is an
independent prognostic marker for RFP and OS
irrespective of VSCC type
The better OS of the two categories displaying stronger
intraepithelial infiltration than altered-immune suppressed
and immune-desert VSCC suggested an important role for
intraepithelial T cells on clinical outcome. For each T-cell
subset the median cell count (Additional file 8) and the
optimized cut-off point, as determined by ROC curve ana-
lysis, was used to categorize the patients tumor into low or
high infiltrated and subsequently its impact on clinical out-
come was determined. High intraepithelial infiltration with
CD3+ T cells, in particular of CD3+CD8−Foxp3− T cells
was strongly associated with longer RFP (p = 0.001) and OS
(p = 0.004). A strong infiltration with CD3+PD1+ T cells
was also associated with a longer RFP (p = 0.032). The
intraepithelial infiltration with CD3+CD8+ T cells or
CD3+CD8−Foxp3+ Tregs was not prognostic for clin-
ical outcome (Fig. 3; Additional file 9). Importantly,
the prognostic power of CD3+CD8−Foxp3− T cells for
RFP was retained when only the HPVnegVSCC were
analyzed (Additional file 9). To sustain this notion, the
impact of tumor infiltrating CD3+CD8−Foxp3− T cells
in clinical outcome was corrected for age, and p53 and
HPV status (Additional file 10). In the univariate
analysis, only high CD3+CD8−Foxp3− counts and age
correlated with RFP. In the multivariate analysis, high
infiltration with CD3+CD8−Foxp3− T cells but not age
was associated with longer RFP (HR 3.30 (1.22–8.94),
Fig. 1 HPVposVSCC are highly infiltrated with CD3+ T cells, especially CD3+CD8−Foxp3− and CD3+CD8+Foxp3− cells. The numbers of
intraepithelial (a) and stromal (b) infiltrating CD3 (T cells), CD3+CD8−Foxp3− (helper T cells), CD3+CD8+Foxp3− (cytotoxic T cells),
CD3+CD8−Foxp3+ (regulatory T cells) and CD3+PD1+ T cells as cells/mm2 for HPV-negative healthy labia (n = 10), and HPVposVSCC (n = 23),
HPVnegVSCC/p53wt (n = 20) and HPVnegVSCC/p53abn (n = 22) patients. CD3+Tbet+ T cells were counted on a subset of the total cohort of 10
HPVposVSCC, 6 HPVnegVSCC/p53wt and 5 HPVnegVSCC/p53abn. VSCC categorization was based on HPV-PCR, p16 and p53 IHC as described in
materials and methods. The bars indicate the median cell count, individual samples are indicated by closed circles. Differences between two
groups were calculated with a Mann-Whitney test with the significance indicated with asterisks. (*p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001)
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p = 0.018). Thus, the CD3+CD8−Foxp3− T-cell infiltra-
tion is expected to be an important prognostic marker
for clinical outcome, irrespective of whether these
VSCC are caused by the HPV-derived oncogenes or
other oncogenic pathways (e.g. p53 mutation).
HPVnegVSCC are infiltrated by activated CD8+ and CD4+
effector memory T cells
The vast majority (~ 80%) of vulvar cancers are not in-
duced by HPV. [17] While 78% (18/23) of HPVposVSCC
were strongly infiltrated with CD3+CD8−Foxp3− T cells,
there was also a considerable fraction of HPVnegVSCC
displaying evidence of their immunogenicity with 60%
(12/20) of the HPVnegVSCC/p53wt and 40% (9/22) of the
HPVnegVSCC/p53abn showing high intraepithelial
CD3+CD8−Foxp3− T-cell infiltration and longer RFP and
OS. In order to gain a better understanding of these
tumor-infiltrating T cells in HPVnegVSCC, a serie of fresh
HPVnegVSCC tumor biopsies was used to culture tumor-
infiltrating lymphocytes (TIL; n = 14) and for ex-vivo
phenotypic analysis of freshly dissociated and directly li-
quid nitrogen stored tumor-infiltrating T cells by flow cy-
tometry (n = 12). Upon mitogenic stimulation, the
growing TILs predominantly produced the type I cytokine
IFN-γ and the type 2 cytokine IL-5 at on average similar
concentrations, suggesting the presence of both Th1 and
Th2 cells in these tumors (Fig. 4). Only low concentra-
tions of TNF-α, IL-4 and IL-10 were found.
To analyze the tumor-infiltrating T cells an antibody
mix against CD45, CD3, CD4, CD8, CCR7, CD45RA,
CD103, CD161, PD-1, CD38, HLA-DR and NKG2A was
used to stain the fresh VSCC digests. In addition, PBMC
of healthy female controls (n = 11) and PBMC of
HPVnegVSCC (n = 29) were stained. A combined hier-
archical Stochastical Neighbor Embedding (HSNE) ana-
lysis of the high-dimensional single cell data obtained
from staining the blood and tumor samples resulted in the
identification of several distinct immune populations
(clusters), which were more prominently present or
absent in the tumors or PBMC of the VSCC patients
(Fig. 5a). In order to automatically discover stratifying bio-
logical signatures within VSCC blood and tumor samples,
we made use of the automated and data-driven CITRUS
platform, as an unbiased and thorough correlation-based
tool for mining and inspection of cell subsets at the single
cell level nested within high-dimensional datasets [34].
The CITRUS analysis resulted in ten distinctive
(groups of) lymphocyte populations significantly
higher present in one or more of the three different
types of samples (Fig. 5b). The CD4 and CD8 distri-
bution within the total CD3+ T-cell population did
not differ between PBMC and tumors of VSCC
Fig. 2 The T-cell infiltration pattern can be used to classify VSCC into four categories. Categorization of the VSCC based on the pattern of T-cell
infiltration was done according to literature [32, 33]. Depicted are four representative examples of T-cell infiltration patterns: designated immune-
inflamed (a), −deserted (b), −altered excluded (c) and -altered immunosuppressed (d). Altered-excluded tumors show more T cells at the invasive
border rather than in the middle of the stroma. Red = CD3, white = keratin (epithelial area)
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patients (Fig. 5c). Of the five identified CD8+ T-cell
subsets, populations 2, 4, and 5 were significantly
underrepresented in VSCC tumors (Fig. 5d). Popula-
tion 2 comprised CD8+CD161+PD1+CD38+ HLA-DR− ef-
fector memory RA+ T cells (Temra), whereas population 4
(CD8+ Tcm/em) and population 5 (CD8+ Temra) did not
display these markers (Additional file 11). The CD8+ T-cell
population (#1) which was clearly overrepresented in VSCC
tumors, consisted of
CD8+CD103+CD161−NKG2A+/−PD1++CD38++HLA-DR+
Tem cells. Of the five different CD4+ T-cell subsets identi-
fied, population 6 (CD4+PD-1−CD161−CD38++HLA-DR−
naïve T cells) and population 10 (CD4+PD-
1+CD38−CD161−HLA-DR− Tem/cm) were lower in VSCC
than PBMC. In contrast, two populations of CD4+ effector
T cells were found at significantly higher percentages and
comprised CD4+PD-1++CD161−CD38+HLA-DR+Tem (#7)
as well as CD4+PD-1−CD161−CD38−HLA-DR−Tcm/em
(#9). The co-expression of PD-1, CD38 and HLA-DR is in-
dicative for T-cell activation. As such the strong tumor-spe-
cific infiltration of HPVnegVSCC with activated CD8+
(population 1) and CD4+ (population 7) effector T cells
sustains the notion these tumors are immunogenic
and explain why their presence is associated with
better clinical outcome.
For half (6/12) of the freshly digested VSCC samples
enough material was available to characterize the T cell
infiltrate with a second antibody mix against CD3, CD4,
Fig. 3 High numbers of intraepithelial CD3+ and CD3+CD8-Foxp3- T cells are associated with longer overall survival and recurrence-free period.
Kaplan-Meier curves showing overall survival (left) and the recurrence-free period (RFP; right) for VSCC patients with high (red) and low (blue)
numbers of intraepithelial CD3+ (a) and CD3+CD8−Foxp3− (b) and CD3+PD1+ (c) cells/mm2. The patients were grouped based on the best cut-off
value for each subset as determined by receiver operating characteristics (ROC) curve analysis. The most accurate T-cell subset values for either
OS or RFP was used. Cut-off values were for CD3+ T cells 309.4 and 192.7 cells/mm2 for OS and RFP, respectively, and for CD3+CD8−Foxp3− T
82.58 and 61.82 cells/mm2, respectively, and for CD3+PD1+ 37.67 (OS) and 99.96 (RFP) cells/mm2 for CD3+PD1+ cells, respectively. Patients with a
T-cell count < cut-off value were classified as low, the others as high. Statistical significance of the survival distribution was analyzed by log-rank
testing and significant differences were indicated with an asterisk (*p < 0.05, **p < 0.01, *** p < 0.001 and **** p < 0.0001)
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CD8, CD25, CD127, Foxp3, Tim-3, Lag-3 and Tbet. These
samples were analyzed for the presence of different types
of Tregs, Tbet+ cells and the two checkpoint molecules
according to the strategy shown in Additional file 12.
Similar to what was found in the FFPE tissue samples, a
tumor-specific increase in activated and proliferating
(Ki67+) Tregs was observed (Fig. 6a). Furthermore, tumor-
specific increases in the percentages of Tim-3 and Lag-3
Tregs, CD8+ and non-Treg CD4+ T cells were observed
(Fig. 6b), confirming that part of the tumor-infiltrating T
cells has been activated. Last but not least, on average 30%
of the CD8+ and 20% of the non-Treg CD4+ T cells
expressed the transcription factor Tbet, which is in line
with the IFN-γ production of the cultured TILs. Finally,
only a small percentage of the Tregs expressed Tbet
(Fig. 6b).
Based on the cytokine production and the expression
of several checkpoints, transcription factors and activa-
tion markers, we conclude that HPVnegVSCC are infil-
trated with variable numbers of activated type 1 and 2
CD8+ and CD4+ effector T cells as well as Tregs.
Discussion
We asked the question if the observed differences in re-
currence rate and survival between the three subtypes of
VSCC [14, 17], classified by the presence of HPV, the
overexpression of p53 or the absence of both, may have
an immunological background. Our study is the first to
show that a strong infiltration of the tumor cell nests
with helper (CD3+CD8−Foxp3−) T cells is important for
clinical outcome after primary surgery, irrespective of
whether the VSCC are caused by HPV or other onco-
genic pathways, including TP53 mutations. Probable
reasons for the failure to detect this association in previ-
ous studies [6, 9–11] are related to the importance of
the location of the T cells in the tumor and the homo-
geneity in stage and treatment of the VSCC patients
analyzed. In line with the RFP and the percentage of re-
currences found in each of the three subtypes in VSCC,
the percentage of tumors with high intraepithelial helper
T-cell infiltration was the highest in the HPV-driven
VSCC (78%), followed by VSCC not associated with
HPV or p53 overexpression (60%), and the lowest in
VSCC with abnormal p53 expression (40%). Importantly,
these data suggest that T-cell infiltration of VSCC may
be influenced by the oncogenic pathway underlying the
development of a particular VSCC.
Although the helper T cells display the strongest rela-
tionship with clinical outcome, this does not mean that
CD8+ T cells are not important in VSCC. Whenever there
is a strong intraepithelial infiltration with T cells, this is
because both subsets of T cells are present in large num-
bers. Furthermore, we noted a positive association be-
tween the intraepithelial presence of CD3+PD-1+ T cells
and clinical outcome. In-depth flow cytometric analysis
revealed that this PD1+ T-cell population comprised acti-
vated CD4+PD-1++CD161−CD38+HLA-DR+ and
CD8+CD103+CD161−NKG2A+/−PD1++CD38++HLA-DR+
effector memory T cells. Potentially, helper T cells play an
important role in VSCC because a substantial fraction of
VSCC can partially downregulate HLA class I expression
whilst the levels of tumor-expressed HLA class II may go
up [35]. Based on the percentages of T cells co-expressing
the transcription factor Tbet, as counted in the tumor sec-
tions and measured in fresh VSCC by flow cytometry, and
by the detection of IFN-γ and IL-5 in the supernatants of
stimulated TIL, the VSCC-infiltrating T cells are both of a
type 1 and 2 phenotype.
Current treatment of VSCC does not take into account
the differences in etiology and clinical outcome [3]. The
relationship between T-cell infiltration and clinical out-
come suggests that immunotherapy may form a new
treatment option for VSCC, as in other tumor types this
was associated with a better response to immunotherapy
[32, 33]. These other cancer types were categorized into
immune-inflamed (hot), − altered (excluded or sup-
pressed) and -deserted (cold) tumors in order to define
which immunotherapeutic (combination) approach may
work best. For instance, hot tumors show the best
response to checkpoint blockade (e.g. anti-PD1 and anti-
CTLA-4) [32, 33]. Also VSCC could be divided accord-
ing to these four immune phenotypes. Only a few (5 of
65) VSCC were categorized as truly immune-inflamed
while a substantial portion (37%, n = 24) displayed the
immune altered-excluded phenotype. However, the latter
group displayed a significant stronger intraepithelial T
cell infiltration when compared to the immune altered-
Fig. 4 Tumor-infiltrating lymphocytes produce Th1 and Th2
cytokines upon mitogenic stimulation. In vitro expanded T cells from
VSCC were analyzed for their cytokine production following
mitogenic stimulation with 0.5 μg/ml PHA for 4 days, after which
supernatants were harvested and analyzed by cytometric bead array
(CBA) to determine the production of IFN-γ, TNF-α, IL-10, IL-5, IL-4
and IL-2 in pg/mL. Mean (± SEM) cytokine production is shown for
14 HPVnegVSCC
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suppressed phenotype and showed a better OS. Patients
with inflamed and immune altered-excluded VSCC may
be selected for treatment with immunotherapy. In our
study high percentages of intratumoral T cells expressed
PD-1. Others found variable percentages of cases in
which the VSCC (> 30%) or VSCC-infiltrating immune
cells (> 90%) expressed PD-L1 [11, 36, 37], congruent
with our observation that there are varying numbers of
Fig. 5 HPVnegVSCC are infiltrated with highly activated CD4+ and CD8+ effector/memory T cells. PBMC of healthy controls (n = 11) as well as
PBMC (n = 29) and freshly dissociated tumor-derived TIL (n = 12) of HPVnegVSCC patients were analyzed by 13-parameter flow cytometry
analysis. a Hierarchical Stochastical Neighbor Embedding (HSNE) clusters (left) and density plots (right) visualizing the high-dimensional flow
cytometry data in two dimensions for the collective total CD3+ T cells for indicated groups. The identified cell subsets are identified in the cluster
plots by the different colors. b CITRUS automatic discovery of stratifying biological signatures within tumor and blood samples visualizes 10
distinctive populations of CD8+ and CD4+ T cells the total CD3+ immune population. Every cell population represented by a node is divided on
basis of median level of expression of a differently expressed marker into two new nodes (cellular subsets) going from the center (all cells) to the
periphery of the plot. c The distribution of CD4+ and CD8+ T-cell frequencies (mean ± SEM) within the total CD3+ T cell population is depicted for
healthy control and VSCC PBMC and tumors. d Scatter plots with bars displaying frequencies of CD8+ (# 1 to 5; top panel) and CD4+ (# 6 to 10;
bottom panel) T cell populations are given as % of CD8+ and CD4+ cells. (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001)
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tumor-infiltrating T cells which can produce IFN-γ, as in-
dicated by expression of Tbet, and may lead to adaptive
PD-L1 expression [38]. Altogether, this makes a strong
case for the treatment of inflamed and immune altered-
excluded VSCC with PD-1/PD-L1 checkpoint therapy. In-
deed, a first successfully treated case with advanced stage
recurrent vulvar cancer has been reported with PD-L1
blockade [39]. A tumor-specific increase of the CD4+ T-
cell response seems more likely to be achieved by CTLA4-
blockade than by targeting PD-1 [40], arguing for a com-
bination of PD-L1 and CTLA-4 blockade to reinvigorate
the tumor-specific CD4+ T-cell response. Another option
would be the use of an agonistic antibody to OX-40 [41],
which in combination with PD-L1 blockade displayed syn-
ergistic effects on CD4+ T-cell reactivity [40]. Moreover,
treatment of the generally T-cell infiltrated HPVposVSCC
Fig. 6 HPVnegVSCC are infiltrated with activated and Tbet-expressing CD4+ and CD8+ T cells and Tregs. PBMC of healthy controls (n = 12) and
PBMC (n = 34) and freshly dispersed tumors (n = 6) of HPVnegVSCC patients were analyzed by 13-parameter flow cytometry analysis. Scatter plots
with bars displaying (a) frequencies of total Foxp3+ Tregs (left) and proliferating (Ki67+; middle) and Foxp3hi activated Tregs (Foxp3hi aTregs;
right) within CD3+ T cells and (b) frequencies of Tbet+ (top), Tim-3+ (middle) and Lag-3+ (bottom) cells within the CD8+ (left), non-Treg CD4+
(middle) and Foxp3+ Treg (right) T cell populations. (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001)
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may include therapeutic HPV16 vaccination as HPV-
driven oropharyngeal cancers responded well to the com-
bination of checkpoint therapy and therapeutic
vaccination [42].
One-third of our VSCC were phenotyped as immune-
deserted or cold tumors which may exist because of a lack
of antigens or their presentation (immune ignorance), or
because of several deficits leading to a lack of priming or
to tolerance [32, 42]. Apart from the HPV-induced VSCC,
the viral proteins of which may drive a strong T-cell
response similar to what is seen in HPV-driven oropha-
ryngeal cancer [24], 40–60% of the HPVnegVSCC display
strong intraepithelial T cell infiltration. This suggests that
also in these tumors immunogenic tumor antigens are
expressed and presented. Currently, the antigens recog-
nized by T cells in HPVnegVSCC are unknown but the
majority of primary VSCC express for instance the well-
known tumor antigens MAGEA1 and MAGEA4 [43], but
it is unknown if these antigens function as target for the
VSCC-infiltrating T-cells as this still needs to be studied.
We have no data on a direct relation between the level of
T-cell infiltration and the availability of strong tumor anti-
gens expressed by VSCC, but our work on HPV-specific
immunity in different cancers [25], as well as that of
others in for instance melanoma [44–46], suggest that this
is not the case. More likely, a lack of inflammation or
danger signals has played a role in HPVnegVSCC. Intratu-
moral activation of the Stimulator of Interferon Genes
(STING) pathway [44], the use of oncolytic viruses [45],
but also intratumoral injections of toll-like receptor
(TLR)-agonists [46] have been shown to sensitize cold
tumors to checkpoint blockade. For cold VSCC tumors,
the TLR7/8-agonist imiquimod may be a promising topic-
ally applied therapeutic agent. Imiquimod elevates numer-
ous genes involved in the regulation of innate immunity,
resulting in the migration of DC to the application site,
and subsequently the activation of a type 1 T-cell response
[47]. Patients with a precancerous lesion of HPVposVSCC
responded very well to imiquimod therapy [48]. Notably,
imiquimod treatment of breast metastases in the skin not
only converted them from cold to hot, as demonstrated by
a profound infiltration with CD4+ and CD8+ T cells, but
also led to tumor regression [49].
There are several limitations to our study. The correl-
ation between better clinical outcome and intraepithelial
T-cell infiltration was found in a highly homogeneous
patient group with early stage cancer and treated with
surgery. If this relationship also exists in locally ad-
vanced cancer patients treated with (chemo) radiother-
apy has to be determined. Furthermore, next to the
median cell count, we optimized the chance to detect a
statistically significant relation between T-cell subsets
and clinical outcome in a relatively small group of pa-
tients. Hence our results need to be validated in a larger
cohort. In addition, our data suggests that the etiology of
the VSCC may have an impact on its immunogenicity.
While this would fit with the concept that different
oncogenic pathways may influence local immunity [18,
19], the numbers of VSCC analyzed are such that the
outcome can only be used for hypothesis generation.
Moreover, we have not analyzed the myeloid cell com-
ponent, which on itself may impact prognosis and T-cell
function. Finally, less than 20% of VSCC are induced by
HPV. As such, we merely collected small pieces of fresh
tumor tissue and PBMCs from HPVnegVSCC patients.
A more extensive comparison of the tumor-infiltrating
immune phenotypes between HPV-induced and
HPVnegVSCC, therefore, was not possible.
In conclusion, our observation that a strong coordinated
intraepithelial infiltration with T cells is highly associated
with a better clinical course of early stage VSCC after sur-
gery and suggests that this group of patients may benefit
from immunotherapy as an alternative to potential muti-
lating surgery in this delicate anatomical area [3]. In paral-
lel to the use of the different categories of immune cell
infiltrated tumors in other types of cancer [32, 33], these
tumor classifications can also be used to tailor immuno-
therapy approaches in VSCC. Near future studies should
focus on the effects of checkpoint blockade in patients
classified with inflamed and altered-excluded tumors
while patients diagnosed with an immune-deserted (cold)
VSCC may benefit more from therapies that induce acute
inflammation. Furthermore, future studies should assess
the mutational landscape of VSCC as this will reveal if a
tumor-specific (neo)-antigen T-cell repertoire could be
harnessed to treat the HPVnegVSCC as well as assess if
the HPV-specific T-cell repertoire can be exploited to
treat HPVposVSCC.
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